INNOVUS PHARMA INC COM USD0.001 (INNV)

0.28
0.00 1.69
OTC
Prev Close 0.29
Open 0.29
Day Low/High 0.28 / 0.29
52 Wk Low/High 0.03 / 0.66
Volume 165.97K
Exchange OTC
Shares Outstanding 96.61B
Market Cap 27.05M
Div & Yield N.A. (N.A)

Latest News

RecalMax™ Promotes Healthy Brain Function (Photo: Business Wire)

RecalMax™ Promotes Healthy Brain Function (Photo: Business Wire)

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman As Its Chief Financial Officer

With Revenues Climbing, Innovus Pharma Adds Robert E. Hoffman As Its Chief Financial Officer

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

Innovus Pharma Announces The Approval Of The Product Licenses For Zestra®, Zestra Glide®, EjectDelay® And Sensum+® By The Indian FDA (Directorate General Of Health Services) Through Its Partner Khandelwal Laboratories

Innovus Pharma Announces The Approval Of The Product Licenses For Zestra®, Zestra Glide®, EjectDelay® And Sensum+® By The Indian FDA (Directorate General Of Health Services) Through Its Partner Khandelwal Laboratories

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage cash flow positive pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine...

Innovus Pharma Signs License Agreement With Sothema Laboratories For Zestra(R) And Zestra Glide(R) In The Middle East (Excluding Lebanon And Israel), North Africa And West Africa

Innovus Pharma Signs License Agreement With Sothema Laboratories For Zestra(R) And Zestra Glide(R) In The Middle East (Excluding Lebanon And Israel), North Africa And West Africa

Innovus Eligible to Receive Upfront and Up to $171.25 Million U.S. in Sales Milestone Payments Plus Transfer Price

Innovus Pharma Signs License Agreement With Orimed Pharma For Zestra(R), EjectDelay(TM), Sensum+(TM) And Zestra Glide(R) In Canada

Innovus Pharma Signs License Agreement With Orimed Pharma For Zestra(R), EjectDelay(TM), Sensum+(TM) And Zestra Glide(R) In Canada

Innovus Eligible to Receive Up to $94.5 Million CAD in Upfront and Sales Milestone Payments Plus Double-Digit Tiered Royalties

Innovus Pharma Signs Exclusive Marketing Sales And Distribution Agreement With Tramorgan Limited To Market And Distribute Sensum+(TM) In The United Kingdom

Innovus Pharma Signs Exclusive Marketing Sales And Distribution Agreement With Tramorgan Limited To Market And Distribute Sensum+(TM) In The United Kingdom

-Innovus Pharma Eligible to Receive Up to $44 Million in Sales Milestone Payments Based on Tramorgan's Cumulative Sales Plus 50% Royalties on Its Net Sales

Innovus Pharma Announces The Beginning Of Patient Enrollment In Its Post-Marketing EjectDelay(TM) Clinical Study In The Middle East

Innovus Pharma Announces The Beginning Of Patient Enrollment In Its Post-Marketing EjectDelay(TM) Clinical Study In The Middle East

Study Aimed at Quantifying the Delay in Ejaculation Time Achieved by the Use of the Product in Middle Eastern Men

Innovus Pharma Expands Management Team And Adds Chief Financial Officer

Innovus Pharma Expands Management Team And Adds Chief Financial Officer

Lynnette Dillen Brings 20 Years' Experience in Finance, Accounting

Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.

Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.

Adds Two Over the Counter Revenue-Generating Products, Zestra(TM) and Zestra Glide(TM), to Its Female Sexual Health Product Pipeline